{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:06:47Z","timestamp":1793138807578,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"vor","delay-in-days":136,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008982","name":"Qatar National Research Fund","doi-asserted-by":"publisher","award":["UREP31-188-3-051"],"award-info":[{"award-number":["UREP31-188-3-051"]}],"id":[{"id":"10.13039\/100008982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101252","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T18:04:48Z","timestamp":1779300288000},"page":"101252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The rise of selective estrogen receptor modulators (SERMs) in breast cancer therapy: a promising horizon"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-429X","authenticated-orcid":false,"given":"Raed M.","family":"Al-Zoubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1916-9509","authenticated-orcid":false,"given":"Khalil","family":"Garada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5070-7803","authenticated-orcid":false,"given":"Ayman A.","family":"Zarour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-5654","authenticated-orcid":false,"given":"Mai","family":"Elaarag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2848-8698","authenticated-orcid":false,"given":"Ala\u2019a","family":"Farhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1501-1971","authenticated-orcid":false,"given":"Enas A.","family":"Al-Hurani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6747-9927","authenticated-orcid":false,"given":"Sally R.","family":"Al-Zoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0661-3487","authenticated-orcid":false,"given":"Zainab E.","family":"Fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1161-7244","authenticated-orcid":false,"given":"Ahmad R.","family":"Al-Qudimat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0248-4777","authenticated-orcid":false,"given":"Mazhar Salim Al","family":"Zoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-5646","authenticated-orcid":false,"given":"Hiba","family":"Bawadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9656-8367","authenticated-orcid":false,"given":"Zain Z.","family":"Zakaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8363-1582","authenticated-orcid":false,"given":"Abdelali","family":"Agouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9390-4011","authenticated-orcid":false,"given":"Khalid","family":"Alrumaihi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctarc.2026.101252_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101252_bib0002","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101252_bib0003","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2024.13268","article-title":"Estrogen receptor signaling and targets: bones, breasts and brain (Review)","volume":"30","author":"Toumba","year":"2024","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ctarc.2026.101252_bib0004","first-page":"721","article-title":"Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives","volume":"15","author":"Wang","year":"2023","journal-title":"Breast Cancer (Dove Med. Press)"},{"key":"10.1016\/j.ctarc.2026.101252_bib0005","first-page":"525","article-title":"Diagnostic and prognostic biomarkers of luminal breast cancer: where are we now?","volume":"15","author":"H\u00f6ller","year":"2023","journal-title":"Breast Cancer (Dove Med. Press)"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101252_bib0006","article-title":"Current endocrine therapy in hormone-receptor-positive breast cancer: from tumor biology to the rationale for therapeutic tunning","volume":"61","author":"Burciu","year":"2025","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101252_bib0007","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.coph.2010.09.007","article-title":"The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer","volume":"10","author":"McDonnell","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101252_bib0008","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0092-8674(00)81717-1","article-title":"The structural basis of estrogen receptor\/coactivator recognition and the antagonism of this interaction by tamoxifen","volume":"95","author":"Shiau","year":"1998","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101252_bib0009","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1031","article-title":"Tamoxifen: a most unlikely pioneering medicine","volume":"2","author":"Jordan","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9869","key":"10.1016\/j.ctarc.2026.101252_bib0010","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101252_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-13585-0","article-title":"Real-world assessment of thromboembolic risk associated with tamoxifen","volume":"15","author":"Jia","year":"2025","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101252_bib0012","first-page":"529","article-title":"Estrogens in the breast tissue: a systematic review","volume":"22","author":"Yaghjyan","year":"2011","journal-title":"Cancer Causes Control"},{"issue":"1\u20132","key":"10.1016\/j.ctarc.2026.101252_bib0013","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsbmb.2011.02.001","article-title":"Aromatase, aromatase inhibitors, and breast cancer","volume":"125","author":"Chumsri","year":"2011","journal-title":"J. Steroid. Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101252_bib0014","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3390\/ijms20020306","article-title":"Protein coupled estrogen receptor in breast cancer","volume":"20","author":"Hsu","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2026.101252_bib0015","article-title":"Role of estrogen receptors in health and disease","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101252_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0312276","article-title":"The N-terminal activation function AF-1 domain of ERalpha interacts directly with the C-terminal AF-2-holding ligand-binding domain to recruit the coactivator proteins","volume":"19","author":"Liu","year":"2024","journal-title":"PLoS. One"},{"key":"10.1016\/j.ctarc.2026.101252_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4061\/2011\/812540","article-title":"The dynamic structure of the estrogen receptor","volume":"2011","author":"Kumar","year":"2011","journal-title":"J. Amino Acids."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101252_bib0018","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/receptors3020010","article-title":"Estrogen signals through er\u03b2 in breast cancer; what we have learned since the discovery of the receptor","volume":"3","author":"Nagandla","year":"2024","journal-title":"Receptors (Basel)"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101252_bib0019","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1038\/s41467-018-07175-0","article-title":"Oestrogen receptor alpha AF-1 and AF-2 domains have cell population-specific functions in the mammary epithelium","volume":"9","author":"Cagnet","year":"2018","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101252_bib0020","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1097-2765(00)80479-7","article-title":"Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1","volume":"3","author":"Tremblay","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ctarc.2026.101252_bib0021","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.2147\/OTT.S236532","article-title":"ER\u03b1, A key target for cancer therapy: a review","volume":"Volume 13","author":"Liu","year":"2020","journal-title":"Onco Targets. Ther."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101252_bib0022","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.3390\/ijms26073101","article-title":"Harnessing the role of ESR1 in breast cancer: correlation with microRNA, lncRNA, and methylation","volume":"26","author":"Yang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101252_bib0023","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.AOG.0000137349.79204.b8","article-title":"Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation","volume":"104","author":"Grady","year":"2004","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101252_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clbc.2016.07.015","article-title":"Mechanisms that increase stability of estrogen receptor alpha in breast cancer","volume":"17","author":"Tecalco-Cruz","year":"2017","journal-title":"Clin. Breast. Cancer"},{"key":"10.1016\/j.ctarc.2026.101252_bib0025","article-title":"ERalpha and ERbeta homodimers in the same cellular context regulate distinct transcriptomes and functions","volume":"13","author":"Song","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.ctarc.2026.101252_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.587386","article-title":"Estrogen receptor beta (ERbeta): a ligand activated tumor suppressor","volume":"10","author":"Mal","year":"2020","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101252_bib0027","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1073\/pnas.1323719111","article-title":"Differential expression of estrogen receptor alpha, beta1, and beta2 in lobular and ductal breast cancer","volume":"111","author":"Huang","year":"2014","journal-title":"Proc. Natl Acad. Sci. U S A."},{"issue":"32","key":"10.1016\/j.ctarc.2026.101252_bib0028","doi-asserted-by":"crossref","first-page":"19858","DOI":"10.1074\/jbc.272.32.19858","article-title":"Estrogen receptors alpha and beta form heterodimers on DNA","volume":"272","author":"Cowley","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ctarc.2026.101252_bib0029","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40364-020-00223-2","article-title":"The role of estrogen receptor beta in breast cancer","volume":"8","author":"Zhou","year":"2020","journal-title":"Biomark. Res."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101252_bib0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00432-014-1620-8","article-title":"GPER functions as a tumor suppressor in triple-negative breast cancer cells","volume":"140","author":"Wei\u00dfenborn","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101252_bib0031","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00432-014-1620-8","article-title":"GPER functions as a tumor suppressor in triple-negative breast cancer cells","volume":"140","author":"Weissenborn","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101252_bib0032","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fendo.2014.00066","article-title":"GPER function in breast cancer: an overview","volume":"5","author":"Lappano","year":"2014","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"10.1016\/j.ctarc.2026.101252_bib0033","article-title":"ER\u03b1 and er\u03b2 homodimers in the same cellular context regulate distinct transcriptomes and functions","volume":"13","author":"Song","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101252_bib0034","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-26351-z","article-title":"Safety evaluation of selective estrogen receptor degraders (SERDs) using real-world evidence from the FDA Adverse Event Reporting System (FAERS)","volume":"15","author":"Kang","year":"2025","journal-title":"Sci. Rep."},{"issue":"Suppl 1","key":"10.1016\/j.ctarc.2026.101252_bib0035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s43465-023-01071-6","article-title":"Postmenopausal osteoporosis: menopause hormone therapy and selective estrogen receptor modulators","volume":"57","author":"Rani","year":"2023","journal-title":"Indian J. Orthop."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101252_bib0036","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-023-00523-4","article-title":"An emerging generation of endocrine therapies in breast cancer: a clinical perspective","volume":"9","author":"Patel","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101252_bib0037","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/bcr80","article-title":"Estrogen receptor transcription and transactivation: structure-function relationship in DNA- and ligand-binding domains of estrogen receptors","volume":"2","author":"Ruff","year":"2000","journal-title":"Breast Cancer Res."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101252_bib0038","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1039\/C8OB00790J","article-title":"A \"cross-stitched\" peptide with improved helicity and proteolytic stability","volume":"16","author":"Speltz","year":"2018","journal-title":"Org. Biomol. Chem."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101252_bib0039","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/rmb2.12006","article-title":"Molecular mechanism of estrogen-estrogen receptor signaling","volume":"16","author":"Yasar","year":"2017","journal-title":"Reprod. Med. Biol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101252_bib0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1210\/me.2006-0075","article-title":"Ligand-selective interdomain conformations of estrogen receptor-alpha","volume":"21","author":"Padron","year":"2007","journal-title":"Mol. Endocrinol."},{"issue":"25","key":"10.1016\/j.ctarc.2026.101252_bib0041","doi-asserted-by":"crossref","first-page":"14105","DOI":"10.1073\/pnas.94.25.14105","article-title":"Molecular determinants of tissue selectivity in estrogen receptor modulators","volume":"94","author":"Grese","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"24","key":"10.1016\/j.ctarc.2026.101252_bib0042","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2321344121","article-title":"Asymmetric allostery in estrogen receptor-alpha homodimers drives responses to the ensemble of estrogens in the hormonal milieu","volume":"121","author":"Min","year":"2024","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.ctarc.2026.101252_bib0043","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fcell.2017.00009","article-title":"PBX1 as pioneer factor: a case still open","volume":"5","author":"Grebbin","year":"2017","journal-title":"Front. Cell Dev. Biol."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101252_bib0044","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.3390\/cancers13205205","article-title":"FOXA1: a pioneer of nuclear receptor action in breast cancer","volume":"13","author":"Seachrist","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101252_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002368","article-title":"PBX1 genomic pioneer function drives ERalpha signaling underlying progression in breast cancer","volume":"7","author":"Magnani","year":"2011","journal-title":"PLoS. Genet."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101252_bib0046","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1101\/gr.139469.112","article-title":"GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility","volume":"23","author":"Theodorou","year":"2013","journal-title":"Genome Res."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101252_bib0047","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3390\/biomedicines10040748","article-title":"Epigenetic factors as etiological agents, diagnostic markers, and therapeutic targets for luminal breast cancer","volume":"10","author":"Thang","year":"2022","journal-title":"Biomedicines"},{"issue":"19","key":"10.1016\/j.ctarc.2026.101252_bib0048","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.3390\/cancers15194689","article-title":"Estrogen receptor signaling in breast cancer","volume":"15","author":"Miziak","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2026.101252_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4061\/2011\/232435","article-title":"A role for estrogen receptor phosphorylation in the resistance to tamoxifen","volume":"2011","author":"de Leeuw","year":"2011","journal-title":"Int. J. Breast. Cancer"},{"issue":"24","key":"10.1016\/j.ctarc.2026.101252_bib0050","doi-asserted-by":"crossref","first-page":"9199","DOI":"10.1158\/0008-5472.CAN-04-2126","article-title":"Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity","volume":"64","author":"Cui","year":"2004","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101252_bib0051","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/sj.clpt.6100367","article-title":"Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response","volume":"83","author":"Goetz","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101252_bib0052","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab191","article-title":"Endoxifen, an estrogen receptor targeted therapy: from bench to bedside","volume":"162","author":"Jayaraman","year":"2021","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101252_bib0053","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.14107","article-title":"Efflux and uptake transport and gut microbial reactivation of raloxifene glucuronides","volume":"136","author":"Uoti","year":"2025","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"13","key":"10.1016\/j.ctarc.2026.101252_bib0054","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1517\/14656560903127241","article-title":"Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy","volume":"10","author":"Gennari","year":"2009","journal-title":"Expert. Opin. PharmacOther."},{"key":"10.1016\/j.ctarc.2026.101252_bib0055","first-page":"1437","article-title":"Selective estrogen receptor modulators: tissue specificity and clinical utility","volume":"9","author":"Martinkovich","year":"2014","journal-title":"Clin. Interv. Aging"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101252_bib0056","article-title":"Tamoxifen use and risk of endometrial cancer in breast cancer patients: a systematic review and dose-response meta-analysis","volume":"6","author":"Ghanavati","year":"2023","journal-title":"Cancer Rep. (Hoboken)"},{"issue":"27","key":"10.1016\/j.ctarc.2026.101252_bib0057","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2021.36.e186","article-title":"Incidence and risk of venous thromboembolism in bisphosphonates and selective estrogen receptor modulators treatment in Korea","volume":"36","author":"Park","year":"2021","journal-title":"J. Korean Med. Sci."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101252_bib0058","first-page":"102","article-title":"The development of endoxifen for breast cancer","volume":"16","author":"Goetz","year":"2018","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"15","key":"10.1016\/j.ctarc.2026.101252_bib0059","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1021\/jm960255g","article-title":"Conformational studies and electronic structures of tamoxifen and toremifene and their allylic carbocations proposed as reactive intermediates leading to DNA adduct formation","volume":"39","author":"Kuramochi","year":"1996","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101252_bib0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ijc.10454","article-title":"Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study","volume":"100","author":"Pukkala","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2026.101252_bib0061","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS633","article-title":"A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+\/HER2- breast cancer (EVANGELINE)","volume":"41","author":"Goetz","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101252_bib0062","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1015229630260","article-title":"Phase III randomized trial of Droloxifene and Tamoxifen As first-line endocrine treatment of ER\/PgR-positive advanced breast cancer","volume":"73","author":"Buzdar","year":"2002","journal-title":"Breast Cancer Res. Treat."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101252_bib0063","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0165-6147(98)01252-8","article-title":"Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal","volume":"19","author":"Favoni","year":"1998","journal-title":"Trends. Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101252_bib0064","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1210\/en.2018-01095","article-title":"Next-generation ERalpha inhibitors for endocrine-resistant ER+ breast cancer","volume":"160","author":"Fanning","year":"2019","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101252_bib0065","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1124\/mol.105.021931","article-title":"Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of estrogen receptor alpha","volume":"70","author":"Dayan","year":"2006","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101252_bib0066","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0301-2115(98)00278-4","article-title":"Pharmacokinetics of raloxifene and its clinical application","volume":"85","author":"Hochner-Celnikier","year":"1999","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101252_bib0067","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0090-8258(03)00203-8","article-title":"A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer","volume":"90","author":"McMeekin","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101252_bib0068","first-page":"251","article-title":"Arzoxifene: the evidence for its development in the management of breast cancer","volume":"2","author":"Jackson","year":"2008","journal-title":"Core Evid."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101252_bib0069","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1358\/dot.2015.51.2.2281023","article-title":"Bazedoxifene\/conjugated estrogens combination for the treatment of the vasomotor symptoms associated with menopause and for prevention of osteoporosis in postmenopausal women","volume":"51","author":"Palacios","year":"2015","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.ctarc.2026.101252_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2024.107697","article-title":"Overcoming challenges in conducting early phase breast cancer prevention trials: bazedoxifene and conjugated estrogens vs waitlist control","volume":"146","author":"Fabian","year":"2024","journal-title":"Contemp. Clin. Trials"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101252_bib0071","first-page":"3166","article-title":"A new antiestrogen, 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats","volume":"7","author":"Greenberger","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101252_bib0072","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1358\/dot.2006.42.6.973583","article-title":"Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis","volume":"42","author":"Gennari","year":"2006","journal-title":"Drugs Today (Barc)"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101252_bib0073","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1080\/14796694.2025.2481825","article-title":"ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+\/HER2-, ESR1-mutated, metastatic breast cancer","volume":"21","author":"Goetz","year":"2025","journal-title":"Future Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101252_bib0074","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1210\/endo.143.6.8749","article-title":"Genomic and nongenomic mechanisms of nitric oxide synthesis induction in Human endothelial cells by a fourth-generation selective estrogen receptor modulator","volume":"143","author":"Simoncini","year":"2002","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101252_bib0075","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1158\/1940-6207.CAPR-15-0109","article-title":"Clinical trial of Acolbifene in premenopausal women at high risk for breast cancer","volume":"8","author":"Fabian","year":"2015","journal-title":"Cancer Prev. Res. (Phila)"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101252_bib0076","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3390\/cancers17101653","article-title":"Mechanisms and therapeutic strategies for endocrine resistance in breast cancer: a comprehensive review and meta-analysis","volume":"17","author":"Khan","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101252_bib0077","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1158\/1078-0432.CCR-24-2307","article-title":"ESR1 Y537S and D538G mutations drive resistance to CDK4\/6 inhibitors in estrogen receptor-positive breast cancer","volume":"31","author":"Lin","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101252_bib0078","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13058-025-02049-y","article-title":"Palazestrant, a novel oral Complete Estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), in patients with ER+\/HER2- advanced or metastatic breast cancer: phase 1\/2 study results","volume":"27","author":"Hamilton","year":"2025","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101252_bib0079","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-med-052423-122001","article-title":"New oral selective estrogen receptor degraders redefine management of estrogen receptor-positive breast cancer","volume":"76","author":"Pathak","year":"2025","journal-title":"Annu. Rev. Med."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:56:25Z","timestamp":1790913385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":79,"alternative-id":["S2468294226001632"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101252","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The rise of selective estrogen receptor modulators (SERMs) in breast cancer therapy: a promising horizon","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101252"}}